Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Caribou Biosciences, Inc.CRBU · Entity 6445 | Director | February 20, 2026 | February 20, 2026 |
| Metacrine, Inc.MTCR · Entity 115177 | Director | May 18, 2022 | September 06, 2022 |
| Vaxcyte, Inc.PCVX · Entity 1164 | PRESIDENT AND CFO | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Caribou Biosciences, Inc.
Report date February 20, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2036-02-19 | Direct | 45,000 |
Reported balance
After 2026-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 45,000 · Balance 45,000 F1: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.
Metacrine, Inc.
Report date May 18, 2022 · Filed September 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2032-05-17 | Direct | 16,500 |
Reported balance
After 2022-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-18 · Grant · Acquired 16,500 · Balance 16,500 F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders.
Vaxcyte, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,316 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Tax withholding · Disposed 7,155 · Balance 95,316 F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 61,850 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 61,850 F2: Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F2: Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dermira, Inc.
Report date February 20, 2020 · Filed February 25, 2020
Section 16 reporting ended · disclosed 2020-02-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 1
1 source rowRow 1 · 2020-02-20 · Disposition to issuer · Disposed 41,951 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Includes 1,024 shares of Dermira Common Stock acquired by the Reporting Person pursuant to Dermira's Employee Stock Purchase Plan. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51 · Expires 2024-06-04 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-20 · Disposition to issuer · Disposed 120.513 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2024-10-01 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-20 · Disposition to issuer · Disposed 73,287 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2024-10-01 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-20 · Disposition to issuer · Disposed 67,240 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.37 · Expires 2026-02-04 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-20 · Disposition to issuer · Disposed 71,250 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.84 · Expires 2027-02-16 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-20 · Disposition to issuer · Disposed 71,250 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.25 · Expires 2028-02-15 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-20 · Disposition to issuer · Disposed 57,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.42 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-20 · Disposition to issuer · Disposed 65,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-02-20 · Disposition to issuer · Disposed 3,562 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-02-20 · Disposition to issuer · Disposed 5,700 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-02-20 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-02-20 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Includes 1,024 shares of Dermira Common Stock acquired by the Reporting Person pursuant to Dermira's Employee Stock Purchase Plan.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 29, 2024 Filed Mar 5, 2024 02:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $73.82 | $0.00 |
DisclosureSEC source: 0001415889-24-006473 · form4-03052024_020320.xml · derivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-02-28 F3 · derivative.exercise_date: 1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 02:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006473 · form4-03052024_020320.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,474 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001415889-24-004810 · form4-02222024_090246.xml · derivative · entry 5 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 376,827 Underlying: Common Stock · 8,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 340 | $75.80 | $25,772.00 |
DisclosureSEC source: 0001415889-24-004810 · form4-02222024_090246.xml · nonDerivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,474 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,751 | $75.17 | $206,800.92 |
DisclosureSEC source: 0001415889-24-004810 · form4-02222024_090246.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,814 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.69 to $75.57. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,909 | $74.08 | $363,658.72 |
DisclosureSEC source: 0001415889-24-004810 · form4-02222024_090246.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,565 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.66 to $74.64. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001415889-24-004810 · form4-02222024_090246.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:57 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 39,500 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001628280-24-006405 · wk-form4_1708639013.xml · derivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,500 Underlying: Common Stock · 39,500 shares Expires 2034-02-19 F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2025, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001415889-24-001589 · form4-01192024_090136.xml · derivative · entry 6 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 384,827 Underlying: Common Stock · 8,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 23 | $63.35 | $1,457.05 |
DisclosureSEC source: 0001415889-24-001589 · form4-01192024_090136.xml · nonDerivative · entry 5 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,474 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 463 | $61.88 | $28,650.90 |
DisclosureSEC source: 0001415889-24-001589 · form4-01192024_090136.xml · nonDerivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,497 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $61.84 to $62.305. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,127 | $61.19 | $191,344.26 |
DisclosureSEC source: 0001415889-24-001589 · form4-01192024_090136.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,960 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $60.80 to $61.76. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,387 | $60.28 | $264,426.43 |
DisclosureSEC source: 0001415889-24-001589 · form4-01192024_090136.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,087 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $59.77 to $60.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001415889-24-001589 · form4-01192024_090136.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001209191-23-059346 · doc4.xml · derivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 392,827 Underlying: Common Stock · 8,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 117 | $60.79 | $7,112.43 |
DisclosureSEC source: 0001209191-23-059346 · doc4.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,474 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,883 | $60.17 | $474,304.34 |
DisclosureSEC source: 0001209191-23-059346 · doc4.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,591 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $59.79 to $60.77. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001209191-23-059346 · doc4.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:01 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001209191-23-058943 · doc4.xml · derivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 400,827 Underlying: Common Stock · 14,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:01 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 14,000 | $60.22 | $843,080.00 |
DisclosureSEC source: 0001209191-23-058943 · doc4.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,474 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:01 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 14,000 | $5.35 | $74,900.00 |
DisclosureSEC source: 0001209191-23-058943 · doc4.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:51 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001209191-23-056486 · doc4.xml · derivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 414,827 Underlying: Common Stock · 8,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:51 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 124 | $51.95 | $6,441.80 |
DisclosureSEC source: 0001209191-23-056486 · doc4.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,474 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:51 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,876 | $51.12 | $402,621.12 |
DisclosureSEC source: 0001209191-23-056486 · doc4.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,598 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $50.76 to $51.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:51 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001209191-23-056486 · doc4.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2023 Filed Oct 20, 2023 20:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001209191-23-053251 · doc4.xml · derivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 422,827 Underlying: Common Stock · 8,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 18, 2023 Filed Oct 20, 2023 20:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 503 | $46.32 | $23,300.47 |
DisclosureSEC source: 0001209191-23-053251 · doc4.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,474 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $46.29 to $46.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2023 Filed Oct 20, 2023 20:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,497 | $45.89 | $343,999.85 |
DisclosureSEC source: 0001209191-23-053251 · doc4.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,977 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $45.295 to $46.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2023 Filed Oct 20, 2023 20:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001209191-23-053251 · doc4.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 21:34 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 3,568 | $51.00 | $181,968.00 |
DisclosureSEC source: 0001209191-23-048470 · doc4.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,474 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. F2 · balance_after: Includes 1,040 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2023. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 22:09 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,727 | $41.49 | $71,653.23 |
DisclosureSEC source: 0001209191-23-015714 · doc4.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,002 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:09 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $41.67 | $0.00 |
DisclosureSEC source: 0001209191-23-015714 · doc4.xml · derivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2033-03-01 F3 · derivative.exercise_date: 1/48 of shares subject to the option vest on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:09 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015714 · doc4.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,729 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2023 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:10 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 21,500 | $0.00 Strike: $6.12 | $0.00 |
DisclosureSEC source: 0001619856-23-000022 · wf-form4_167719020813142.xml · derivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-02-20 F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 21, 2024, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 23,691 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001209191-23-000947 · doc4.xml · derivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,827 Underlying: Common Stock · 23,691 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $47.95 | $0.00 |
DisclosureSEC source: 0001209191-23-000947 · doc4.xml · derivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2032-12-30 F1 · derivative.exercise_date: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 23,691 | $5.35 | $126,746.85 |
DisclosureSEC source: 0001209191-23-000947 · doc4.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 22:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 3,100 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001209191-22-050941 · doc4.xml · derivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,518 Underlying: Common Stock · 3,100 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 22:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 477 | $26.52 | $12,650.04 |
DisclosureSEC source: 0001209191-22-050941 · doc4.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,538 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $26.465 to $26.56. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 22:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,623 | $26.02 | $68,247.84 |
DisclosureSEC source: 0001209191-22-050941 · doc4.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,015 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.46 to $26.445. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 22:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,100 | $5.35 | $16,585.00 |
DisclosureSEC source: 0001209191-22-050941 · doc4.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 20:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 4,649 | $26.38 | $122,640.62 |
DisclosureSEC source: 0001209191-22-049021 · doc4.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,538 F1 · kind: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| August 29, 2022 Filed Aug 29, 2022 21:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 17,653 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001209191-22-047903 · doc4.xml · derivative · entry 9 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,618 Underlying: Common Stock · 17,653 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| August 29, 2022 Filed Aug 29, 2022 21:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 17,653 | $28.00 | $494,284.00 |
DisclosureSEC source: 0001209191-22-047903 · doc4.xml · nonDerivative · entry 6 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,187 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 29, 2022 Filed Aug 29, 2022 21:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 17,653 | $5.35 | $94,443.55 |
DisclosureSEC source: 0001209191-22-047903 · doc4.xml · nonDerivative · entry 5 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 21:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 1,295 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001209191-22-047903 · doc4.xml · derivative · entry 8 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,271 Underlying: Common Stock · 1,295 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 21:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,295 | $28.00 | $36,260.00 |
DisclosureSEC source: 0001209191-22-047903 · doc4.xml · nonDerivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,187 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 21:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 1,295 | $5.35 | $6,928.25 |
DisclosureSEC source: 0001209191-22-047903 · doc4.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2022 Filed Aug 29, 2022 21:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 17,052 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001209191-22-047903 · doc4.xml · derivative · entry 7 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,566 Underlying: Common Stock · 17,052 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| August 25, 2022 Filed Aug 29, 2022 21:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 17,052 | $28.00 | $477,456.00 |
DisclosureSEC source: 0001209191-22-047903 · doc4.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,187 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.